CD109 Antibody (496920) [Alexa Fluor® 594]

• Reactivity: Hu
• Applications: Flow
• Clone: 496920
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 594
• Concentration: Please see the vial label for concentration. If unlisted please contact technical services.

CD109 Antibody (496920) [Alexa Fluor® 594] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human CD109
  Val22-Ser1268 (Tyr703Ser & Thr1241Met)
  Accession # Q6YHK3
• Specificity: Detects human CD109 in direct ELISAs.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Gene: CD109
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25-1 ug/10^6 cells
• Application Notes: Flow Cytometry: Please use 0.25-1 ug of conjugated antibody per 10e6 cells.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.
• Preservative: 0.09% Sodium Azide
• Concentration: Please see the vial label for concentration. If unlisted please contact technical services.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CD109 Antibody (496920) [Alexa Fluor® 594]

• 150 kDa TGF-beta-1-binding protein
• activated T-cell marker CD109
• C3 and PZP-like alpha-2-macroglobulin domain-containing protein 7
• CD109 antigen (Gov platelet alloantigens)
• CD109 antigen
• CD109 molecule
• CD109
• CPAMD7
• CPAMD7r150
• DKFZp762L1111
• FLJ38569
• FLJ41966
• Gov platelet alloantigens
• p180
• Platelet-specific Gov antigen
• RP11-525G3.1

Background

CD109 is a GPI-anchored member of the alpha-2-macroglobulin (A2M) and complement family of proteins (1). Mature human CD109 contains a bait region with recognition sequences for multiple proteases, an internal thioester bond, and a domain similar to the receptor binding domain of A2M (2). Cleavage of A2M family proteins within the bait region activates the thioester bond to promote covalent bonding to nucleophilic groups in adjacent molecules (3, 4). Within the region included in this recombinant protein, human CD109 shares 71-73% amino acid (aa) sequence identity with mouse and rat CD109. It shares 27-33% aa sequence identity with A2M and complement factors C3, C4, and C5. Alternate splicing of human CD109 generates two isoforms with short deletions and one that is truncated within the bait region. CD109 is expressed on activated T cells and platelets, hematopoietic stem cells, megakaryocyte precursors, vascular endothelial cells, basal and myoepithelial cells of secretory glands, and squamous cell carcinomas (2, 5-9). It is produced as a 170-180 kDa glycoprotein that is autocatalytically processed to 150 kDa and 120 kDa forms (2, 6, 10). CD109 on keratinocytes binds TGF-beta and associates with TGF-beta RI and TGF-beta RII, resulting in inhibition of TGF-beta signaling (11). Polymorphisms of CD109 include the platelet-specific Gov antigen and the blood group ABH antigens (12, 13). Alloantibodies directed against these antigens result in unsuccessful platelet transfusions, neonatal alloimmune thrombocytopenia, and posttransfusion purpura (14).

1. Travis, J. and G.S. Salvesen (1983) Annu. Rev. Biochem. 52:655.
2. Lin, M. et al. (2002) Blood 99:1683.
3. Christensen, U. and L. Sottrup-Jensen (1984) Biochemistry 23:6619.
4. Wallis, R. et al. (2007) J. Biol. Chem. 282:7844.
5. Murray, L.J. et al. (1999) Exp. Hematol. 27:1282.
6. Haregewoin, A. et al. (1994) Cell. Immunol. 156:357.
7. Hasegawa, M. et al. (2007) Pathol. Int. 57:245.
8. Brashem-Stein, C. et al. (1988) J. Immunol. 140:2330.
9. Hashimoto, M. et al. (2004) Oncogene 23:3716.
10. Solomon, K.R. et al. (2004) Gene 327:171.
11. Finnson, K.W. et al. (2006) FASEB J. 20:1525.
12. Schuh, A.C. et al. (2002) Blood 99:1692.
13. Kelton, J.G. et al. (1998) J. Lab. Clin. Med. 132:142.
14. Rozman, P. (2002) Transpl. Immunol. 10:165.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: CD109
• Uniprot:
  • Q6YHK3()